{"id":5644,"date":"2007-07-06T07:38:00","date_gmt":"2007-07-06T07:38:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&#038;p=5644"},"modified":"2022-03-31T15:04:11","modified_gmt":"2022-03-31T15:04:11","slug":"therapeiltic-leukocytapheresis-for%e3%80%80infiammatory-bowel-disease","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/es\/professional\/scientific-corner\/therapeiltic-leukocytapheresis-for%e3%80%80infiammatory-bowel-disease\/","title":{"rendered":"Therapeutic leukocytapheresis for inflammatory bowel disease"},"content":{"rendered":"<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1473050207001164#!\">Abbi R.Saniabadi, HiroyukiHanai, KenFukunaga, KojiSawada, ChikakoShima, IngvarBjarnason, RobertLofberg<\/a>, https:\/\/doi.org\/10.1016\/j.transci.2007.08.003<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>The inference that\u00a0<a href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/granulocyte\">granulocytes<\/a>\u00a0and monocytes\/macrophages (GM) are part of the\u00a0<a href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/immunopathogenesis\">immunopathogenesis<\/a>\u00a0of\u00a0<a href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/inflammatory-bowel-disease\">inflammatory bowel disease<\/a>\u00a0(IBD) and hence should be targets of therapy stems from observations of elevated, and activated GM in patients with IBD. The\u00a0<a href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/adacolumn\">Adacolumn<\/a>\u00a0can selectively deplete GM by adsorption (GMA) and in patients with IBD. GMA has been associated with significant clinical efficacy together with sustained suppression of inflammatory cytokine profiles. Additionally, GMA depleted proinflammatory CD14<sup>+<\/sup>CD16<sup>+<\/sup>\u00a0<a href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/monocyte\">monocytes<\/a>\u00a0and was followed by an increase in CD4<sup>+<\/sup>\u00a0T lymphocytes including the regulatory CD4<sup>+<\/sup>CD25<sup>high+<\/sup>Foxp3 phenotype. Hence, GMA could be a non-pharmacologic therapy for IBD with potential to spare steroids and other unsafe pharmacologic preparations.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1473050207001164\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1473050207001164<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Abbi R.Saniabadi, HiroyukiHanai, KenFukunaga, KojiSawada, ChikakoShima, IngvarBjarnason, RobertLofberg, https:\/\/doi.org\/10.1016\/j.transci.2007.08.003 The inference that\u00a0granulocytes\u00a0and monocytes\/macrophages (GM) are part of the\u00a0immunopathogenesis\u00a0of\u00a0inflammatory bowel disease\u00a0(IBD) and hence should be targets of therapy stems from observations of elevated, and activated GM in patients with IBD. The\u00a0Adacolumn\u00a0can selectively deplete GM by adsorption (GMA) and in patients with IBD. GMA has been associated [&hellip;]<\/p>\n","protected":false},"template":"","scientific_tags":[237,589,566,159,79,314,179,173,354,306],"class_list":["post-5644","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-cd14-cd16","scientific_tags-cd25highcd4-tcell","scientific_tags-corticosteroid-sparing-effect","scientific_tags-crohns-disease","scientific_tags-cytokines","scientific_tags-digestive","scientific_tags-foxp3-t-cells","scientific_tags-moa","scientific_tags-steroid-sparing","scientific_tags-ulcerative-colitis"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Therapeutic leukocytapheresis for inflammatory bowel disease - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/therapeiltic-leukocytapheresis-for\u3000infiammatory-bowel-disease\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Therapeutic leukocytapheresis for inflammatory bowel disease - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Abbi R.Saniabadi, HiroyukiHanai, KenFukunaga, KojiSawada, ChikakoShima, IngvarBjarnason, RobertLofberg, https:\/\/doi.org\/10.1016\/j.transci.2007.08.003 The inference that\u00a0granulocytes\u00a0and monocytes\/macrophages (GM) are part of the\u00a0immunopathogenesis\u00a0of\u00a0inflammatory bowel disease\u00a0(IBD) and hence should be targets of therapy stems from observations of elevated, and activated GM in patients with IBD. The\u00a0Adacolumn\u00a0can selectively deplete GM by adsorption (GMA) and in patients with IBD. GMA has been associated [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/therapeiltic-leukocytapheresis-for\u3000infiammatory-bowel-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2022-03-31T15:04:11+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/therapeiltic-leukocytapheresis-for%e3%80%80infiammatory-bowel-disease\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/therapeiltic-leukocytapheresis-for%e3%80%80infiammatory-bowel-disease\/\",\"name\":\"Therapeutic leukocytapheresis for inflammatory bowel disease - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2007-07-06T07:38:00+00:00\",\"dateModified\":\"2022-03-31T15:04:11+00:00\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/therapeiltic-leukocytapheresis-for%e3%80%80infiammatory-bowel-disease\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Therapeutic leukocytapheresis for inflammatory bowel disease - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/therapeiltic-leukocytapheresis-for\u3000infiammatory-bowel-disease\/","og_locale":"es_ES","og_type":"article","og_title":"Therapeutic leukocytapheresis for inflammatory bowel disease - Adacyte","og_description":"Abbi R.Saniabadi, HiroyukiHanai, KenFukunaga, KojiSawada, ChikakoShima, IngvarBjarnason, RobertLofberg, https:\/\/doi.org\/10.1016\/j.transci.2007.08.003 The inference that\u00a0granulocytes\u00a0and monocytes\/macrophages (GM) are part of the\u00a0immunopathogenesis\u00a0of\u00a0inflammatory bowel disease\u00a0(IBD) and hence should be targets of therapy stems from observations of elevated, and activated GM in patients with IBD. The\u00a0Adacolumn\u00a0can selectively deplete GM by adsorption (GMA) and in patients with IBD. GMA has been associated [&hellip;]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/therapeiltic-leukocytapheresis-for\u3000infiammatory-bowel-disease\/","og_site_name":"Adacyte","article_modified_time":"2022-03-31T15:04:11+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/therapeiltic-leukocytapheresis-for%e3%80%80infiammatory-bowel-disease\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/therapeiltic-leukocytapheresis-for%e3%80%80infiammatory-bowel-disease\/","name":"Therapeutic leukocytapheresis for inflammatory bowel disease - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2007-07-06T07:38:00+00:00","dateModified":"2022-03-31T15:04:11+00:00","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/therapeiltic-leukocytapheresis-for%e3%80%80infiammatory-bowel-disease\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner\/5644","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/media?parent=5644"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific_tags?post=5644"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}